Kraj: Kanada
Język: angielski
Źródło: Health Canada
TICAGRELOR
TEVA CANADA LIMITED
B01AC24
TICAGRELOR
90MG
TABLET
TICAGRELOR 90MG
ORAL
6X10/60
Prescription
PLATELET AGGREGATION INHIBITORS
Active ingredient group (AIG) number: 0152934001; AHFS:
APPROVED
2021-04-21
_ _ _Teva-Ticagrelor _ _Page 1 of 61_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-TICAGRELOR Ticagrelor Tablets Tablets, 60 mg and 90 mg, Oral Ph. Eur. Platelet Aggregation Inhibitor Teva Canada Limited 30 Novopharm Court Toronto, Ontario M1B 2K9 Date of Initial Authorization: April 19, 2021 Date of Revision: January 31, 2023 Submission Control No: 266401 _ _ _Teva-Ticagrelor _ _Page 2 of 61_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Cardiovascular 01/2023 7 WARNINGS AND PRECAUTIONS, Central Sleep Apnea 01/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics .............................................................................................................. 4 2 CONTRAINDICATIONS ...................................................................................................4 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations ........................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 5 4.4 Administration ...................................................................................................... 7 4.5 Missed Dose....................................... Przeczytaj cały dokument